DUPIXENT was first approved for atopic dermatitis (eczema) in 2017. Since that first approval, it has been expanded to five more indications, with the potential for three more approvals in 2025. In addition, it has seen five expansions. Through it all I have worked my way up from lead copywriter to associate creative director. I’ve gained launch experience, and have led the last three indication launches/age expansions for the drug.

In addition, I helped to create digital guidelines for the brand across web, social, and paid digital ads. These guidelines have played a part in DUPIXENT being recognized by Gartner as a Genius Brand Performer 3 years running. After placing fourth in 2019 and sixth in 2020, DUPIXENT placed first overall in 2021 and 2022, and 2nd in 2023.

I’ve also gained experience collaborating with the agency of record on brand planning and campaign shoots, and other partner agencies on ambassador video shoots and projects.

Our team has grown from five people (four art directors and a copywriter in 2018) to 15 people today. I have helped mentor and manage five copywriters, four who have been promoted internally or externally.

On the client side, I’ve been able to build trusted relationships that have led to award-winning creative across multiple touch points. Because of this, we’ve been able to take risks with our creative and pitch projects that may not have been approved otherwise.